A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
Clinical trial NCT02036502 · TERMINATED
Trial details
- NCT number
- NCT02036502
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-02-14
- Primary completion
- 2020-03-19
- Enrollment
- 77
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.